ROZLYTREK's Market Growth Reflects Transforming Treatment for NTRK and ROS1-Positive Cancers | DelveInsight
DelveInsight's "ROZLYTREK Market Size, Forecast, and Market Insight Report" highlights the details around ROZLYTREK, an ...
Pharmac Funding Decision Will Increase Medicines Access
Pharmac has today announced their decision to fund six medicines for cancer, including a combination treatment, and one ...
CURE12d
FDA Approval of Ensacove Adds to the Toolkit for ALK-Positive NSCLC
An expert explained the importance of the FDA’s approval of Ensacove for patients with ALK-positive non-small cell lung ...
Seeking Alpha1mon
Nuvation Bio: Pending Approval Shot In ROSL+ NSCLS Looks A Major Upside Catalyst
Nuvation Bio, listed via SPAC in 2021, and acquired AnHeart Therapeutics last year, gaining taletrectinib, a promising ROS1 inhibitor indicated for non-small cell lung cancer. The FDA has accepted ...
pharmaphorum7y
NICE does not recommend Pfizer's Xalkori
The National Institute for Health and Care Excellence (NICE) today announced final draft guidance on Pfizer's Xalkori (crizotinib) and has not recommended it for use in previously-treated ...